DrugPatentWatch Database Preview

Details for Patent: 7,709,444

« Back to Dashboard

Which drugs does patent 7,709,444 protect, and when does it expire?

Patent 7,709,444 protects ERAXIS and is included in one NDA.

This patent has twenty-three patent family members in seventeen countries.

Summary for Patent: 7,709,444

Title:	Echinocandin pharmaceutical formulations containing micelle-forming surfactants
Abstract:	Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.
Inventor(s):	Milton; Nathaniel (Indianapolis, IN), Moder; Kenneth Philip (West Lafayette, IN), Sabatowski; James Lawrence (Holland, MI), Sweetana; Stephanie Ann (Bloomington, IN)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	11/103,798
Patent Claim Types: see list of patent claims	Formulation; Compound; Process; Use;

Drugs Protected by US Patent 7,709,444

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vicuron	ERAXIS	anidulafungin	POWDER;INTRAVENOUS	021632-001	Feb 17, 2006		RX	Yes	Yes			Y			TREATMENT OF FUNGAL INFECTIONS
Vicuron	ERAXIS	anidulafungin	POWDER;INTRAVENOUS	021632-002	Nov 14, 2006		RX	Yes	Yes			Y			TREATMENT OF FUNGAL INFECTIONS

International Family Members for US Patent 7,709,444

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	294571
Australia	3249100
Australia	776782
Brazil	0009249